15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
- Massimo Mannelli⇑,
- Elena Rapizzi,
- Rossella Fucci,
- Letizia Canu,
- Tonino Ercolino1,
- Michaela Luconi and
- William F Young Jr2
- Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio’, University of Florence, Viale Pieraccini 6, 50139
Florence, Italy
1Endocrinology Unit, Careggi Hospital, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
2Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA
- Correspondence should be addressed to M Mannelli; Email: massimo.mannelli{at}unifi.it
Abstract
The discovery of SDHD as a pheochromocytoma/paraganglioma susceptibility gene was the prismatic event that led to all of the subsequent work highlighting the key roles played by mitochondria in the pathogenesis of these tumors and other solid cancers. Alterations in the function of tricarboxylic acid cycle enzymes can cause accumulation of intermediate substrates and subsequent changes in cell metabolism, activation of the angiogenic pathway, increased reactive oxygen species production, DNA hypermethylation, and modification of the tumor microenvironment favoring tumor growth and aggressiveness. The elucidation of these tumorigenic mechanisms should lead to novel therapeutic targets for the treatment of the most aggressive forms of pheochromocytoma/paraganglioma.
- Revision received 19 June 2015
- Accepted 23 June 2015
- Made available online as an Accepted Preprint 25 June 2015
- © 2015 Society for Endocrinology